Screener / SEC EDGAR /CIK 0001821825 /10-K filed Feb 24, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Pharmaceuticals

Organon & Co. OGN

Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. 10-K, Item 1

Employees
10,000
Headquarters
Jersey City, NJ
CEO
Joseph Morrissey
Next results
around Feb 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $6.2B through the costs to a net profit of $187.0M · income statement of the 10-K

3% net margin
Revenue to Gross profit: $3.3BRevenue to Cost of revenue: $2.9BGross profit to Net profit: $187.0MGross profit to Costs, tax, other: $3.1B Revenue: $6.2B REVENUE $6.2B −3% Y/Y Gross profit: $3.3B · 53% margin GROSS PROFIT $3.3B 53% margin · −11% Y/Y Cost of revenue: $2.9B · 47% of revenue COST OF REVENUE $2.9B 47% of revenue Net profit: $187.0M · 3% margin NET PROFIT $187.0M 3% margin · −78% Y/Y Costs, tax, other: $3.1B · 50% of revenue COSTS, TAX, OTHER $3.1B 50% of revenue
Gross profit $3.3B 53% margin · −11% Y/Y
Net profit $187.0M 3% margin · −78% Y/Y
The full income statement, year by year

OGN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: -2.9%, above 7% of 154 peers (their median 10.5%) REVENUE GROWTH -2.9% · above 7% Gross margin: 53.1%, above 30% of 107 peers (their median 63.8%) GROSS MARGIN 53.1% · above 30% Net margin: 3.5%, above 42% of 153 peers (their median 6.8%) NET MARGIN 3.5% · above 42% FCF margin: 11.1%, above 53% of 144 peers (their median 9.9%) FCF MARGIN 11.1% · above 53%
OGN Peer median Below the median

What changed

55 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 24, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Critical audit matters changed
    New this year: Annual Goodwill Impairment Assessment - U.S. Reporting Unit (“As described in Notes 2 and 11 to the consolidated financial statements, the Company’s goodwill balance was $4,153 million, of which $921 million relates to the U.S. reporting unit as of December 31, 2025. The Company recorded a goodwill impairment charge of $301 million during the fourth quarter of”). Same as last year: U.S. Rebate Accruals - Medicaid and Managed Care Rebates
  • Material weakness in internal control
    “Additionally, while the Audit Committee’s investigation is complete, we identified material weaknesses in our internal control over financial reporting and, as a result, our management has determined that our disclosure controls and procedures and internal control over financial reporting were not effective as of December 31, 2024 or as of December 31, 2025.”
  • Receivables -2.0% ($1.4B to $1.3B) vs revenue -2.9% ($6.4B to $6.2B), +0.9 pts apart
8 more checks with nothing to note
  • Cash from operations $700.0M vs net income $187.0M (FY ending Dec 31, 2025)
  • Inventory +6.4% ($1.3B to $1.4B) vs revenue -2.9% ($6.4B to $6.2B), +9.4 pts apart
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

55 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 55 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The imposition of tariffs on, or other trade restrictions or domestic sourcing requirements in, the territories and countries where we, our partners, suppliers, or customers do business, as well as any retaliatory actions with respect to such actions, could have a material adverse effect on our business, financial condition, results of…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The U.S. presidential administration has reached several bilateral trade agreements that seek to cap tariffs on imports into the U.S., including an agreement with the EU that would limit U.S. tariffs to 15% on certain brand pharmaceutical and to keep tariffs on generic medicines at 0%. The United States may reach additional trade…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The completion of the self-initiated Audit Committee internal investigation and the subsequent implementation of our remediation plan has been time-consuming and expensive and may result in significant additional expense and/or litigation. As discussed in Item 9A. “Controls and Procedures”, after concerns regarding our sales practices…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    In the ordinary course of business, we and our third-party providers collect, store and transmit large amounts of confidential

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$6.2B$6.3B$6.4B$6.2B
Net income$917.0M$1.0B$864.0M$187.0M
Operating cash flow$858.0M$799.0M$939.0M$700.0M
Free cash flow$662.0M$548.0M$764.0M$538.0M

Revenue, FY2019 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$6.2B ▼ 2.9% in FY2025

FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Organon & Co., Jersey City, NJ · from the 10-K filed Feb 24, 2026

Organon & Co. (“Organon,” the “Company,” “we,” “our,” or “us”) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across women’s health and general medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 countries and territories.

Headquarters
Jersey City, NJ
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Apr 30, 2026

Employees, at the top of the page: "As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OGN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.